


ORIGINAL PAPER

Open Access



Comparative in vitro treatment of mesenchymal stromal cells with GDF-5 and R57A induces chondrogenic differentiation while limiting chondrogenic hypertrophy

Manuel Weißberger^{1,2*†} , Mike Wagenbrenner^{1,3†}, Joachim Nickel^{4†}, Rasmus Ahlbrecht^{1,5}, Torsten Blunk⁵, Andre F. Steinert^{1,6} and Fabian Gilbert^{3,5}

Abstract

Purpose Hypertrophic cartilage is an important characteristic of osteoarthritis and can often be found in patients suffering from osteoarthritis. Although the exact pathomechanism remains poorly understood, hypertrophic de-differentiation of chondrocytes also poses a major challenge in the cell-based repair of hyaline cartilage using mesenchymal stromal cells (MSCs). While different members of the transforming growth factor beta (TGF- β) family have been shown to promote chondrogenesis in MSCs, the transition into a hypertrophic phenotype remains a problem. To further examine this topic we compared the effects of the transcription growth and differentiation factor 5 (GDF-5) and the mutant R57A on in vitro chondrogenesis in MSCs.

Methods Bone marrow-derived MSCs (BMSCs) were placed in pellet culture and in-cubated in chondrogenic differentiation medium containing R57A, GDF-5 and TGF- β 1 for 21 days. Chondrogenesis was examined histologically, immunohistochemically, through biochemical assays and by RT-qPCR regarding the expression of chondrogenic marker genes.

Results Treatment of BMSCs with R57A led to a dose dependent induction of chondrogenesis in BMSCs. Biochemical assays also showed an elevated glycosaminoglycan (GAG) content and expression of chondrogenic marker genes in corresponding pellets. While treatment with R57A led to superior chondrogenic differentiation compared to treatment with the GDF-5 wild type and similar levels compared to incubation with TGF- β 1, levels of chondrogenic hypertrophy were lower after induction with R57A and the GDF-5 wild type.

Conclusions R57A is a stronger inducer of chondrogenesis in BMSCs than the GDF-5 wild type while leading to lower levels of chondrogenic hypertrophy in comparison with TGF- β 1.

Keywords Bone marrow, Cartilage, Chondrogenesis, Chondrogenic hypertrophy, Mesenchymal stromal cell, GDF-5, R57A

[†]Manuel Weißberger, Mike Wagenbrenner and Joachim Nickel contributed equally to this work.

*Correspondence:

Manuel Weißberger
manuel.weissenberger@googlemail.com

Full list of author information is available at the end of the article

Background

Limited regenerative capacity of hyaline cartilage in combination with demographic changes have led to a sharp rise of patients suffering from osteoarthritis (OA) as well as the number of total joint arthroplasties [20]. Although patient satisfaction after primary hip or knee arthroplasty is high, joint replacements are limited by service life and revision, surgery remains complicated [17, 22, 50]. This has led to increasing interest in cell-based regenerative treatments for OA involving mesenchymal stromal cells (MSCs) [3]. MSCs can be isolated from various adult tissues. As defined by the International Society for Cellular Therapy (ISCT) MSCs express a characteristic set of surface antigens, are multipotent and adhere to plastic [16].

In order to optimize chondrogenic differentiation potential and limit unwanted hypertrophy during chondrogenesis of MSCs we and others investigated different combinations of scaffolds, growth factors and signaling pathways [23, 30]. Nonetheless, the ideal combination of growth factors has not yet been discovered [42]. Our earlier studies proved that various members of the transforming growth factor (TGF)- β superfamily such as TGF- β 1, bone morphogenetic protein (BMP)-2 and BMP-4 promote and influence chondrogenic differentiation of MSCs in vitro [36, 41, 43, 44].

However, increasing cell hypertrophy characterized by the elevated expression and formation of collagen type X (COL X; encoded by COL10A1) remains one of the major obstacles observed during late chondrogenesis of MSCs in vitro. Chondrogenic hypertrophy signals the preliminary stage prior to cell apoptosis or mineralization of the extracellular matrix (ECM). This process naturally occurs during endochondral ossification (EO) in the growth plate leading to a replacement of hyaline cartilage with mineralized bone tissue but complicates cell-based methods of cartilage repair [4, 25, 42]. In accordance, in vivo data have shown that treatment of cartilage defects with MSCs and chondrogenic growth factors may lead to formation of osteophytes and tissue hypertrophy [10, 41]. Interestingly, earlier research has shown that transcription factors such as sex-determining region Y-type high-mobility-group-box (SOX) 9 (encoded by *SOX9*) not only promote chondrogenesis but also limit unwanted hypertrophy during chondrogenic differentiation of MSCs [48, 51].

Advanced understanding of different effects of growth factors on MSCs have led to extensive research regarding other growth factors influencing chondrogenesis and chondrogenic hypertrophy such as growth differentiation factor-5 (GDF-5) [8, 14, 35]. GDF-5 is a member of the TGF- β superfamily and plays an important role during early bone and cartilage formation by increasing cell adhesion and therefore promoting prechondrogenic

condensation [5]. Earlier research showed that GDF5 may regulate cartilage homeostasis by enhancing the production of matrix components in healthy chondrocytes and simultaneously limiting the activity of different proteases [7, 12]. Further, in vitro exposure of MSCs to GDF-5 led to an increased expression of chondrogenic and hypertrophy markers [1, 2, 9]. Just like BMP-2 and BMP-4 the GDF-5 wildtype binds to two variations of the type I BMP-receptor (BRI) called BRIA and BRIB [21]. Although the structure of GDF-5 is highly similar to that of BMP-2, the affinity of GDF-5 to BRIB is almost 12-fold higher than to BRIA [19]. Interestingly, this receptor affinity can be abrogated by exchanging Arginine 57 in GDF-5 with Alanine which leads to the generation of the mutant GDF-5 R57A (R57A) [19]. Previous studies have shown that while R57A mimics the receptor affinity to BRIA of BMP-2 it suppressed BMP-2-mediated expression of alkaline phosphatase (ALP; encoded by *ALP*) a marker gene for chondrogenic hypertrophy [19, 40, 44].

Therefore, the goal of our current in vitro study was to further examine possible differences regarding the effects of treatment with GDF-5 and the mutant R57A on chondrogenic differentiation and hypertrophy in bone marrow-derived MSCs (BMSCs) during pellet culture in vitro.

Methods

Generation and growth of GDF-5 and R57A

Plasmids harboring cDNAs which encode for the mature parts of either GDF5 or the mutein GDF5- R57A were both generated by standard cloning techniques and cloned into the expression plasmid RBSIIN25x/o as described earlier [31]. The resulting plasmids were then transformed into the *E. coli* strain BL21 (DE3). Protein expression was initiated in bacterial cultures by adding Isoropyl-thiogalactoside (IPTG) to a final concentration of 1 mM. After three hours of incubation at 37 °C cells were harvested by centrifugation and lysed by sonication. The proteins were subsequently isolated from inclusion bodies, refolded and purified by cation exchange chromatography using SP-Sepharose as resin as described [31]. Purified proteins were afterwards dialyzed against water and stored at -80 °C until further use.

Cultivation of BMSCs

Human BMSCs were isolated from 5 different donors aged from 33 to 65 years (mean age 53 years). All donors underwent total hip arthroplasty (THA) following informed consent and as approved by the institutional review board of the University of Würzburg as reported in our earlier studies [33, 44]. Bone marrow was harvested from the femoral head. Collected samples were spun, resuspended and seeded in plastic cell culture

flasks (Greiner Bio-One GmbH, Frickenhausen, Germany). Harvested cells were cultivated in standard cell culture medium containing DMEM/Ham's F12 supplemented, 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PS) (all Life Technologies, Thermo Fischer Scientific, Dreieich, Germany). Culture medium changes were performed every 2 to 3 days (d). After reaching confluency cells were trypsinated, counted and placed in pellet cultures as subsequently described.

Pellet cell culture

BMSCs were placed in pellet cultures as described in our previous studies [44]. To summarize BMSCs were resuspended in serum free DMEM supplemented with 1% ITS + Premix, 1×10^{-7} mol/l dexamethasone, 37.5 mg/ml Ascorbat-2-phosphate and 1 mM pyruvate (all Sigma, St Louis, MO, USA). Next 300 μ l aliquots containing 3×10^5 cells were placed in V-bottomed 96-well plates (Corning, Corning, NY, USA) to promote formation of small aggregates. Untreated controls were maintained as negative controls and cultured in the standard medium mentioned above. Other samples were incubated with 500 ng/ml or 1000 ng/ml of R57A or GDF-5. Lastly pellet cultures treated with 10 ng/ml recombinant TGF- β 1 (R&D Systems, Minneapolis, MN, USA) served as internal controls to compare effects regarding successful chondrogenesis and chondrogenic hypertrophy [45, 49, 51]. After cultivation at 37 °C, 5% CO₂ pellet formation was observed within the first 24 h. Medium changes were performed every 2 to 3 d before pellets were harvested after a total of 21 d of chondrogenesis.

Histology and immunohistochemistry

Pellets aggregates were dehydrated, embedded in paraffin and sectioned after being fixed in 4% paraformaldehyde (all Sigma) as described previously [44]. Alcian Blue (Sigma) stainings for detection of proteoglycans in pellet sections were performed as outlined in our earlier research [44]. Further, immunohistochemical stainings were performed using following compilation of antibodies and pre-digestion: collagen type II (COL II; encoded by COL2A1)-pepsin (1 mg/ml; Sigma)/monoclonal anti-COL II antibodies (Acris Antibodies GmbH, Hiddenhausen, Germany) and COL X—0.25% trypsin (Sigma)/polyclonal anti-COL X antibodies (Calbiochem, Bad Soden, Germany). Diaminobenzidine staining (DAB Kit; Sigma) following treatment with Advance™ HRP link and Advance™ HRP enzyme (Dako, Hamburg, Germany) was used to visualize immunohistochemical stainings. Sections were subsequently counterstained with hemalaun (Merck, Darmstadt, Germany). Non-immune IgGs (Sigma) replacing primary antibodies were used as negative controls. For detailed information regarding

antibodies and immunohistochemistry please refer to our previous work [45, 49, 51].

Biochemical assay

Biochemical assays were used to investigate cell proliferation, formation of glycosaminoglycans (GAG) and alkaline phosphatase (ALP) activity at 3, 7, 14 and 21 d as described earlier and following the respective user's manual [44]. Adenosine triphosphate (ATP) assays using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) were used to examine cell proliferation. After digestion with papain (1 μ g/ml; Sigma) the content of GAG in harvested pellets was measured with the Blyscan™ Sulfated Glycosaminoglycan Assay (Biocolor Ltd, Newtownabbey, Northern Ireland) by reaction with 1,9-dimethylmethylene blue. The ALP activity was measured in an Enzyme-linked Immunosorbent Assay (ELISA) reader by the conversion of p-nitrophenol-phosphate to p-nitrophenol and inorganic phosphate via absorbance at 405 nm to determine the Quant-iT™ PicoGreen® kit (Invitrogen GmbH, Darmstadt, Germany).

Isolation of RNA and RT-qPCR analysis

During chondrogenic differentiation RNA was extracted from BMSCs pellets at 3, 7, 14 and 21 d using Trizol reagent and purification steps involving DNase (Invitrogen) treatment following the user's manual of the NucleoSpin RNA II kit (Macherey–Nagel GmbH, Düren, Germany). At days 3, 7, 14 and 21 RNA was extracted from the pellets. For the reverse transcription random hexamer primers (Table 1) and Bio-Script reverse transcriptase (Bioline GmbH, Luckenwalde, Germany) were used with 2 μ g RNA from each group. Quantitative PCR (qPCR) was performed in triplicate with 1 μ L cDNA, 10 μ L KAPA SYBR FAST Universal 2 \times qPCR Master Mix (peqlab Biotechnologie GmbH) and 1 μ L of gene specific primers. The quantitative RT-PCR (RT-qPCR) was performed eventually with Opticon DANN Engine (MJ Research, Waltham, USA) using the following protocol: 95 °C for 3 min; 40 cycles: 95 °C for 15 s; 58 °C for 20 s; 72 °C for 30 s; the melting curve was analyzed after the last cycle. Calculation of the results was performed using the $\Delta\Delta$ -CT Method. All sequences, annealing temperatures, cycle numbers and product sizes of forward and reverse primers used for COL2A1, SOX9, COL10A1 and ALP are listed in Table 1. As pointed out in our previous studies Elongation factor 1 α (encoded by EEF1A) was used as the housekeeping gene [52].

Statistical analysis

All data derived from experiments involving ATP assays, GAG assays, DNA assays, ALP assays or RT-PCR were

Table 1 Primer details for quantitative RT-PCR. EEF1A, Elongation factor 1 α ; COL2A1, collagen type II alpha 1; COL10A1, collagen type X alpha 1; ALP, alkaline phosphatase; SOX9, sex-determining region Y-box 9

Gene	primer sequences (5'-3')	annealing temperature (°C)	product size (base pairs)	cycles	MgCl ₂
<i>Housekeeping gene for internal control</i>					
EEF1A	Sense: AGGTGATTATCCTGAACCATCC Antisense: AAAGGTGGATAGTCTGAGAAGC	54.0	234	25	1 x
<i>Chondrogenic marker genes</i>					
COL2A1	Sense: TTTCCCAGGTCAAGATGGTC Antisense: CTTCAGCACCTGTCCACCA	58.0	374	35	1x
SOX9	Sense: ATCTGAAGAAGGAGAGCGAG Antisense: TCAGAAGTCTCCAGAGCTTG	58.0	263	35	1x
<i>Chondrogenic hypertrophy marker genes</i>					
COL10A1	Sense: CCCTTTTGTGCTAGTATCC Antisense: CTGTTGTCCAGGTTTCTGGCAC	54.0	468	25	1x
ALP	Sense: TGGAGCTTCAGAAGCTCAACACCA Antisense: ATCTCGTTGTCTGAGTACCAGTCC	51.0	454	35	1x

performed using BMSCs derived from five different donors ($n=5$) and expressed as mean values \pm standard deviation. Each experiment was performed in triplicate or quadruplicate ($n=3$ to 4). Data was checked for normal distribution using the Kolmogorov–Smirnov and Shapiro–Wilk test. Non-parametric testing was performed in case of not normally distributed data. For evaluation of statistically significant expression rates in the ATP assays, GAG assays and DNA assays for the R57A, GDF-5 and TGF- β incubation medium, respectively, the Kruskal–Wallis-Test including a post-hoc Dunn-Bonferroni-Test was used. Differences in the relative expression level of chondrogenic and hypertrophic marker genes were also determined using the Kruskal–Wallis-Test and statistically significant differences between the R57A, GDF-5 and TGF- β incubation medium were evaluated using the post-hoc Dunn-Bonferroni Test. P -values < 0.05 were considered statistically significant.

Results

Histological and immunohistochemical analysis of chondrogenic differentiation

After 21 d all differentiated pellets showed clear signs of chondrogenic differentiation as judged by Alcian Blue stainings after treatment with R57A (500 ng/ml and 1000 ng/ml) and GDF-5 (500 ng/ml and 1000 ng/ml) or incubation with TGF- β 1 (Fig. 1, Alcian Blue, a-e). Similar results were observed for immunohistochemical stainings of COL II (Fig. 1, Collagen II, a-e). Intensity of

Alcian blue stainings and immunohistochemical stainings of COL II increased in dose dependent manner after incubation of BMSCs with R57A (Fig. 1, Alcian Blue/Collagen II, a-b). Alcian Blue staining intensity and intensity of immunohistochemical stainings of COL II was highest after treatment with 1000 ng/ml of R57A (Fig. 1, Alcian Blue/Collagen II, b). Staining intensity was lower in differentiated cultures treated with 500 ng/ml of R57A and TGF- β 1 in comparison to other differentiated cultures treated with 1000 ng/ml of R57A and GDF-5 (500 ng/ml and 1000 ng/ml) (R57A (Fig. 1, Alcian Blue/Collagen II, a, e). Staining intensity was lowest in differentiated pellet cultures treated with GDF-5 independent of concentrations used (Fig. 1, Alcian Blue/ Collagen II, c-d).

Regarding the phenotype of pellet sections respective pellets treated with R57A and TGF- β 1 showed more chondrone-like structures (Fig. 1, Alcian Blue, a-b, e). Pellets treated with R57A also showed more homogenic stainings of COL II following chondrogenic differentiation (Fig. 1, Collagen II, a-b).

Controls showed negative Alcian Blue stainings and negative immunohistochemical stainings for COL II (Fig. 1, Alcian Blue/Collagen II, f).

In addition, controls and pellets which were treated with 10 ng/ml TGF- β 1 as well as GDF-5 independent of the concentrations used showed clearly positive immunohistochemically stainings for the marker of chondrogenic hypertrophy COL X (Fig. 1, Collagen X, c-e). In comparison, staining intensity regarding immunohistochemically




Fig. 1 Histological and immunohistochemical analysis of chondrogenic differentiation and hypertrophic differentiation in mesenchymal stromal cells after incubation with R57A, GDF-5 and TGF- β 1 21 days in pellet culture. Mesenchymal stromal cells (MSCs) were incubated with 500 ng/ml (a) and 1000 ng/ml (b) of the mutant R57A, 500 ng/ml (c) and 1000 ng/ml (d) of growth and differentiation factor 5 (GDF-5) or transforming growth factor beta (TGF- β)1 (e) in pellet cultures for 21 days. Untreated cultures treated with standard cell culture medium were maintained as negative controls (f). Clear signs of chondrogenesis as judged by histological Alcian Blue stainings and immunohistochemical stainings of Collagen type II (Collagen II) were observed in all pellet cultures treated with R57A, GDF-5 and TGF- β 1 (Alcian Blue, Collagen II, a-e) while internal controls showed no positive staining (Alcian Blue, Collagen II, f). All cultures showed slightly positive immunohistochemical stainings of the hypertrophy marker collagen type X (Collagen X, a-e). Representative samples were captured at low (50x; black bar = 100 μ m) and high (200x; black bar = 50 μ m) magnification. GDF-5, growth and differentiation factor 5; MSCs, mesenchymal stromal cells; TGF- β transforming growth factor beta

staining of COL X seemed lower in pellets which were treated with 500 ng/ml and 1000 ng/ml of R57A (Fig. 1, Collagen X, a-b).

Biochemical analysis of cell proliferation, GAG content and ALP activity

ATP assays showed a steady increase of cell proliferation in control cultures over 21 d (Fig. 2, a, control). Cell proliferation remained mostly constant in differentiated pellet cultures during the same time span (Fig. 2, a). Interestingly cell proliferation in pellets increased after 7 d before declining again until d 21 after treatment with 500 ng/ml R57A (Fig. 2, a, R57A 500 ng/ml). After 7 d of chondrogenesis cell proliferation was significantly higher in cultures treated with 500 ng/ml R57A (Fig. 2, a, 7, R57A 500 ng/ml) and after 14 d cell proliferation was significantly lower in cultures treated with 10 ng/ml TGF- β 1 (Fig. 2, a, 14, TGF- β 1 10 ng/ml) in comparison to other differentiated cultures and negative controls. Besides these findings cell proliferation did not differ significantly

at 3, 7, 14 or 21 d after treatment R57A, TGF- β 1 or GDF-5 independent of concentrations used (Fig. 2, a).

Quantitative examination of GAG synthesis showed little increase in control cultures on day 7 but did not differ significantly in comparison to points of evaluation over the course of 21 d (Fig. 2, b, control). Pellet cultures treated with 500 or 1000 ng/ml of R57A, 1000 ng/ml of GDF-5 and TGF- β 1 showed an increase of GAG content in comparison to control cultures after 7 d of chondrogenesis (Fig. 2, b, 7). A similar trend was observed after 14 d of treatment of pellet cultures with 500 ng/ml of GDF-5 (Fig. 2, b, 14). GAG synthesis in differentiated pellet cultures peaked after 14 d (Fig. 2, b, 14) besides from pellet cultures treated with 500 ng/ml R57A which reached highest values after 21 d of chondrogenic differentiation (Fig. 2, b, 21 days in culture). After 7 d of chondrogenesis GAG synthesis was significantly higher in cultures treated with 500 ng/ml R57A (Fig. 2, b, 7, R57A 500 ng/ml) and after 21 d GAG synthesis was significantly higher in cultures treated with 500 ng/ml R57A (Fig. 2, b, 21,




Fig. 2 Assay of cell proliferation ATP activity, GAG content and ALP activity after 21 days of chondrogenic differentiation in pellet cultures derived from five different donors. Pellet cell cultures containing mesenchymal stromal cells (MSCs) were incubated in chondrogenic differentiation medium containing 500 ng/ml and 1000 ng/ml of the mutant R57A, 500 ng/ml and 1000 ng/ml of growth and differentiation factor 5 (GDF-5) or transforming growth factor beta (TGF-β)1 for 21 days to induce chondrogenesis. Untreated cultures treated with standard cell culture medium were maintained as negative controls. Adenosine Triphosphate (ATP)-Assays (a) were performed to examine cell proliferation after 3, 7, 14 and 21 days. Glycosaminoglycan (GAG)-Assays (b) were conducted to examine the quantitative synthesis of the chondrogenic marker protein GAG in respective pellets after 3, 7, 14 and 21 days. In addition, alkaline phosphatase (ALP)-Assays (c) were performed to evaluate relative ALP-activity after 3, 7, 14 and 21 days. Asterix (*) represent significant differences ($P < 0.05$) compared to negative control samples at this particular time. The respective group of pictured bars refer to MSCs treated as controls, with R57A 500 ng/ml, with R57A 1000 ng/ml, with GDF-5 500 ng/ml, with GDF-5 1000 ng/ml and TGF-β1 10 ng/ml (from left to right). ATP, Adenosine Triphosphate; ALP, alkaline phosphatase; GAG, Glycosaminoglycan; GDF-5, growth and differentiation factor 5; MSCs, mesenchymal stromal cells; TGF-β, transforming growth factor beta

R57A 500 ng/ml) and 10 ng/ml TGF-β1 (Fig. 2, b, 21, TGF-β1 10 ng/ml) in comparison to other differentiated cultures and negative controls.

Further relative ALP activity was elevated in all chondrogenic differentiated pellet cultures in comparison to control cultures during 21 d of chondrogenesis (Fig. 2, c). After 14 and 21 d of chondrogenesis ALP activity was increased in all chondrogenic differentiated pellets in comparison to control cultures (Fig. 2, c, 14–21). Interestingly, relative ALP activity decreased between 7 and 21 d after treatment with 500 ng/ml of R57A (Fig. 2, c, 7–21, R57A 500 ng/ml). Finally, relative ALP activity was significantly higher in pellets treated with TGF-β1 (Fig. 2, c, 21, TGF-β1 10 ng/ml) and 1000 ng/ml of R57a (Fig. 2, c, 21, R57A 1000 ng/ml) after 21 d of chondrogenesis.

RT-qPCR analysis of the expression of chondrogenic and hypertrophic marker genes

To compare effects of treatment of BMSCs with R57A, GDF-5 and TGF-β1 on chondrogenesis and possible hypertrophic differentiation we examined the relative expression of respective marker genes after 3, 7, 14 and 21 d (Fig. 3). In this context COL2A1 and COL10A1 refer to the genes coding the respective COL II and COL X alpha 1 chains.

Control cultures expressed low levels of chondrogenic marker genes COL2A1 and SOX9 over the course of 21 d of chondrogenesis. In contrast, the expression of all chondrogenic marker genes were

elevated in all chondrogenic differentiated cultures treated with R57A, GDF-5 or TGF-β1 after 14 and 21 d of chondrogenesis in comparison to control cultures (Fig. 3, Collagen II/ SOX9, 14–21). Expression of COL2A1 was significantly higher in cultures treated with 1000 ng/ml R57A in comparison to control cultures after 7 and 21 d of chondrogenesis (Fig. 3, Collagen II, 7, R57A 1000 ng/ml). Expression of SOX9 was significantly higher in pellets treated with 10 ng/ml TGF-β1 after 7, 14 and 21 d of chondrogenesis in comparison to control cultures (Fig. 3, SOX9, 7–21, TGF-β1 10 ng/ml).

Further, 21 d of chondrogenesis led to non-significant elevation of relative gene expression levels of hypertrophy marker gene COL10A1 in all chondrogenic differentiated cultures in comparison to control cultures over the course of 21 d (Fig. 3, Collagen X, 3–21).

Gene expression of ALP showed slight upregulation during 21 d of pellet culture (Fig. 3, Alkaline phosphatase, 3–21). Interestingly, at 14 and 21 d expression of ALP increased in all chondrogenic differentiated cultures (Fig. 3, Alkaline phosphatase, 14–21). However, gene expression of ALP remained lowest in pellets treated with 500 ng/ml R57A (Fig. 3, Alkaline phosphatase, 21). However, the expression of COL10A1 and ALP was significantly higher in pellet cultures treated with TGF-β1 after 21 d of chondrogenesis (Fig. 3, Collagen X/Alkaline phosphatase, 21, TGF-β1 10 ng/ml) in comparison to differentiated cultures or negative controls.




Fig. 3 Mean changes in the relative expression of chondrogenic and hypertrophic marker genes ± standard deviation as measured by RT-qPCR in mesenchymal progenitor cells at the end of the chondrogenic differentiation period. Mesenchymal stromal cells (MSCs) derived from bone marrow of five different patients were incubated with chondrogenic differentiation medium containing 500 ng/ml and 1000 ng/ml of the mutant R57A, 500 ng/ml and 1000 ng/ml of growth and differentiation factor 5 (GDF-5) or transforming growth factor beta (TGF-β)1 for 21 days for 21 days. Untreated cultures treated with standard cell culture medium were maintained as negative controls. The mean changes in the relative expression of the chondrogenic (a) marker genes—collagen type II (Collagen II) and sex-determining region Y-type high-mobility-group-box (SOX) 9—as well as the hypertrophic (b) marker genes—collagen type X (Collagen X) and alkaline phosphatase (ALP)—are pictured, respectively. Error bars represent the range of changes in the mean expression of specific marker genes in differentiated cell cultures from which the standard deviations were calculated. Elongation factor 1α (EEF1α) was used as the housekeeping gene and for internal controls. Primer details are illustrated in Table 1. Asterisks (*) represent significant differences ($P < 0.05$) compared to negative control samples at this particular time. The respective group of pictured bars refer to MSCs treated as controls, with R57A 500 ng/ml, with R57A 1000 ng/ml, with GDF-5 500 ng/ml, with GDF-5 1000 ng/ml and TGF-β1 10 ng/ml (from left to right). RT-PCR was performed using BMSCs derived from five different donors ($n = 5$) and each experiment was performed in triplicate or quadruplicate ($n = 3$ to 4). d, days; GDF-5, growth and differentiation factor 5; TGF-β, transforming growth factor beta

Discussion

MSCs have emerged as a promising cell source for the regenerative treatment of articular cartilage defects using tissue engineering. However, terminal hypertrophic differentiation of MSCs as seen during endochondral ossification remains a major obstacle in cell-based cartilage repair [11, 26, 42].

We and others have previously shown that the delivery of different transcription and growth factors to MSCs can enhance chondrogenic differentiation while simultaneously promoting or mitigating hypertrophic

differentiation [36, 43, 44, 52]. While different members of the TGF-β superfamily led to progression towards chondrogenic hypertrophy gene transfer of *SOX9* showed a decreased trend towards chondrogenic hypertrophy during chondrogenic differentiation [51]. In our current study we examined the effects of different doses (500 ng/ml and 1000 ng/ml) of GDF-5, the mutant R57A as well as TGF-β1 on chondrogenic differentiation of human BMSCs.

Our present in vitro study showed that treatment of BMSCs with different doses of GDF-5, R57A and TGF-β1

led to successful chondrogenic differentiation as shown by Alcian Blue stainings, immunohistochemical stainings of COL II and elevated relative expression of chondrogenic marker genes. Intensity of Alcian Blue and COL II stainings seemed to be stronger in pellet cultures after treatment with R57A and TGF- β 1 when compared to pellets treated with GDF-5 independent of the concentrations used. After 21 d of chondrogenesis GAG content increased in all differentiated pellet cultures in comparison to control cultures. After 21 d of chondrogenesis GAG content was significantly higher in pellet cultures treated with 1000 ng/ml R57A and 10 ng/ml TGF- β 1 in comparison to other differentiated cultures and negative controls. In addition, chondrogenic differentiation of BMSCs led to increased relative expression of chondrogenic marker genes *COL2A1* and *SOX9* in comparison to control cultures. After 7 and 21 d of chondrogenesis the expression levels of chondrogenic marker genes were significantly higher in pellets treated with 1000 ng/ml R57A and 10 ng/ml TGF- β 1. In addition, we observed intense immunohistochemical stainings of the hypertrophy marker COL X after treatment with GDF-5 and TGF- β 1. After 21 d of chondrogenesis all differentiated pellet cultures showed an increased expression of *ALP* in comparison to control cultures. After 21 d of chondrogenic differentiation pellet cultures treated with 10 ng/ml TGF- β 1 showed a significant increase in the expression levels for both *ALP* and *COL10A1*. In addition, 21 d of chondrogenesis in pellet culture also led to a significantly increased ALP activity in cultures treated with 1000 ng/ml R57A and 10 ng/ml TGF- β 1. This is in line with our previous studies in which incubation of pellet cultures with TGF- β 1 led to clear chondrogenic differentiation accompanied by stronger hypertrophic and osteogenic de-differentiation in comparison to other prochondrogenic transcription or growth factors [51]. While the incubation of BMSC with the growth factors R57A, GDF-5 and TGF- β 1 for 21 d in pellet cultures in vitro led to successful chondrogenic differentiation, TGF- β 1 and higher concentrations of R57A may promote hypertrophic and osteogenic differentiation. Differences regarding the immunohistochemical staining of COL X and RT-qPCR results may be due to phasal upregulation resulting in delayed protein formation and expression of respective marker genes [49].

Earlier research by Coleman et al. found that incubation of BMSCs with GDF-5 led to significantly enhanced chondrogenesis as shown by increased production of COL II and GAG [9]. Despite these findings incubation with GDF-5 simultaneously led to increased SMAD phosphorylation and elevated relative expression of hypertrophic marker genes such as *COL10A1* and *ALP* [9]. Previous studies linked SMAD phosphorylation

to increased expression of hypertrophic marker genes and mineralization of the ECM [15]. Similar results were found after incubation of embryonic stem cells (ESCs), embryonic chick mesenchymal cultures or other MSC-subpopulations with GDF-5 in vitro [8, 34].

Further Fang et al. showed that adenoviral gene transfer of GDF-5 to MSCs derived from adipose tissue led to enhanced chondrogenic differentiation as shown by increased production of GAG and elevated expression of chondrogenic marker genes [14]. In contrast to the findings in this study Fang et al. showed that adenoviral gene transfer of GDF-5 led to superior effects on chondrogenesis in MSCs compared to incubation with TGF- β 1 [14]. Similar to our present study Xiaowen et al. confirmed pro-chondrogenic effects of GDF-5 on fetal MSCs but found GDF-5 to be less stimulatory than TGF- β 1 [2]. Interestingly, combined treatment with GDF-5 and TGF- β 1 had synergistic effects on chondrogenesis [2].

However, in line with our results hypertrophic differentiation and increased expression of hypertrophic or osteogenic marker genes was observed in most of the studies which examined the effects of GDF-5 on chondrogenesis in multiple cell types [2, 8, 9, 14]. In line with these results adenoviral gene transfer leading to overexpression of GDF-5 in MSCs led to osteogenic differentiation in vitro and in vivo [6]. Interestingly, incubations of MSCs with GDF-5 in hypoxic conditions led to increased chondrogenic differentiation as well as decreased hypertrophic differentiation as shown by expression of COL X in comparison to normoxic conditions [47].

GDF-5 is also known as cartilage-derived morphogenetic protein-1 (CDMP-1) or BMP-14 and is closely related to other members of the TGF- β superfamily such as BMP-2 [19, 39]. Earlier research revealed that GDF-5 acts by binding to the transmembrane serine/threonine kinase receptors BR1A, BR1B and BR1I [19]. Binding to these receptors activates downstream SMAD dependent pathways through phosphorylation [9, 46]. Activation of SMAD pathways is closely associated with cell proliferation, cell differentiation and changes of the gene expression of chondrogenic marker genes such as *COL2A1* or aggrecan (encoded by *ACAN*) [29, 46]. Chondrogenesis involves the condensation, differentiation and maturation of MSCs. During this process GDF-5 has been shown to promote cell adherence similar to pellet cell-culture supporting enhanced prechondrogenic cell condensation [8, 24]. Interestingly, single-nucleotide polymorphisms (SNPs) of the *GDF-5* gene are associated with susceptibility to OA [13, 28]. In addition, GDF-5 expression has shown to be upregulated in chondrocytes derived from articular cartilage in patients suffering from OA [37].

During embryological limb development condensed cells differentiate into chondrocytes which later become

hypertrophic before calcifying, undergoing apoptosis and being replaced by bone tissue [8]. While GDF-5 is believed to play an important role in homeostasis of adult hyaline cartilage, research has shown that GDF-5 also promotes cell condensation and hypertrophic differentiation during limb development and chondrogenic differentiation of MSCs in vitro [6, 9, 46]. In accordance, research has linked mutations of GDF-5 to multiple cartilage and joint disorders [8, 18]. Out of all BRI receptor variations GDF-5 naturally shows a tenfold greater binding affinity to BRIB in comparison to BRIA. In contrast, BMP2 possesses similar binding affinity to BRIA and BRIB [19, 32]. We and others have shown that incubation of MSCs with BMP2 or genetic transfer of BMP2 to MSCs has shown to significantly enhance chondrogenesis in vitro and in vivo [38]. However, BMP2 has also shown to promote osteogenesis in MSCs via SMAD-dependent pathways as shown by increased expression of osteogenic marker genes and formation of specific matrix molecules [38]. Concordant with these findings BMP2 enhanced unwanted hypertrophic differentiation during chondrogenesis of MSCs in various earlier studies [41, 42, 52].

The mutant R57A is formed by exchanging Arginine 57 with Alanine. Nickel et al. pointed out that this exchange of amino acids in R57A led to a higher receptor affinity towards BRIA in comparison to GDF5 making R57A a BMP2-mimic [19, 32]. Previous research pointed out that GDF-5-mutants may affect osteogenesis and chondrogenesis in MSCs differently than the GDF-5-wildtype [27]. Klammert et al. showed that incubation of different cell lines with R57A or GDF-5 led to reduced overall ALP activity and dose-dependent inhibition of BMP2-mediated ALP activity [19]. Consistent with differences in the receptor affinity towards BRIA effects were greater when using R57A [19]. In addition, BMP2 led to endochondral, heterotopic ossification upon implantation in rat muscles while this was not the case for R57A and GDF-5 [19]. Coimplantation of BMP2 with GDF-5 or R57A led to reduced heterotopic ossification pointing out their assumed role as context-dependent BMP2-antagonists [19]. In our current study we found no differences regarding the effects of R57A and GDF-5 on hypertrophic differentiation in MSCs independent of the concentrations used.

In summary, our present in vitro study showed that GDF-5, R57A and TGF- β 1 all induce chondrogenic differentiation in pellet cultures of BMSCs. Although chondrogenic differentiation may be superior when using 500 ng/ml and 1000 ng/ml R57A as well as 10 ng/ml TGF- β 1 in comparison to GDF-5 as indicated by histological and immunohistochemical stainings, incubation with 1000 ng/ml R57A and 10 ng/ml TGF- β 1

also led to a significant increase in gene expression of hypertrophic marker genes and ALP activity. However, one major weakness to our current study is the missing quantitative analysis of histological stainings, meaning examination and comparison of chondrogenesis based on histological data is only a rough analysis based on the visual judgement of the researcher. Further in vitro and in vivo studies are necessary to further examine the pro-chondrogenic and hypertrophic potential of the mutant R57A in tissue engineering (TE) and therapeutically relevant differences compared to recombinant GDF-5.

Conclusion

The high affinity variant R57A of the growth factor GDF-5 is a strong inducer of chondrogenesis in BMSC-pellet cultures. However, potential risk of ossification and hypertrophy during chondrogenic differentiation has to be considered. Further research has to focus on identifying appropriate biomaterials for the delivery of these factors to investigate the in vivo capability for TE based approaches in cartilage repair.

Abbreviations

ALP (encoded by ALP)	Alkaline phosphatase
BMSCs	Bone marrow-derived mesenchymal stromal cells
BMP	Bone Morphogenetic Protein
BR	BMP receptor
CDMP-1	Cartilage-derived morphogenetic protein-1
cDNA	Complementary DNA
COL II	Collagen type II
COL X	Collagen type X
COL2A1	collagen type II alpha 1
COL10A1	collagen type X alpha 1
d	Days
ECM	Extracellular matrix
EEF1A	Elongation factor 1 α
EO	Endochondral ossification
FBS	Fetal bovine serum
GDF-5	Growth and differentiation factor 5
GDF-5 R57A	R57A
MSCs	Mesenchymal stromal cells
ISCT	International Society for Cellular Therapy
PBS	Phosphate buffered saline
PS	Penicillin/streptomycin
RT-qPCR	Quantitative reverse-transcriptase polymerase chain reaction
SMAD	Homologues of the Drosophila protein, mothers against decapentaplegic (Mad) and the Caenorhabditis elegans protein Sma
SOX9, Sox-9	Sex-determining region Y-box 9
TE	Tissue engineering
THA	Total hip arthroplasty

Authors' contributions

All authors have read and approved the manuscript and contributed to the study design, data analysis, interpretation of data and drafting and revision of the manuscript. Experiments: F.G.; Writing of manuscript and design of the tables and figures: Ma.W., Mi.W., J.N., R.A., A.S., F.G.; All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. This publication was supported by the Open Access Publication Fund of the University of Würzburg.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study design and experiments were approved by the institutional review board of the University of Würzburg (Approval number: 2016020502). In addition, participating patients agreed to the use of collected and examined surgical waste after undergoing total hip replacement surgery.

Consent for publication

Informed consent was obtained from all subjects involved in the study.

Competing interests

The authors declare no conflict of interests.

Author details

¹Department of Orthopaedic Surgery, Center for Musculoskeletal Research, Julius-Maximilians-University Würzburg, König-Ludwig-Haus, Würzburg, Germany. ²Department of Orthopedic Surgery, University of Würzburg, König-Ludwig-Haus, Brettreichstraße 11, 97074 Würzburg, Germany. ³Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. ⁴Department of Tissue Engineering and Regenerative Medicine, Julius-Maximilians-University Würzburg, University Hospital, Würzburg, Germany. ⁵Department of Trauma-, Hand-, Plastic- and Reconstructive Surgery, Julius-Maximilians-University Würzburg, University Hospital, Würzburg, Germany. ⁶Current address; Department of Orthopaedic, Trauma, Shoulder and Arthroplasty Surgery, Rhön-Klinikum, Campus Bad Neustadt, Bad Neustadt, Germany.

Received: 28 December 2022 Accepted: 8 March 2023

Published online: 21 March 2023

References

- Ayerst BI, Smith RA, Nurcombe V, Day AJ, Merry CL, Cool SM (2017) Growth differentiation factor 5-mediated enhancement of chondrocyte phenotype is inhibited by heparin: implications for the use of heparin in the clinic and in tissue engineering applications. *Tissue Eng Part A* 23:275–292
- Bai X, Xiao Z, Pan Y, Hu J, Pohl J, Wen J et al (2004) Cartilage-derived morphogenetic protein-1 promotes the differentiation of mesenchymal stem cells into chondrocytes. *Biochem Biophys Res Commun* 325:453–460
- Berebichez-Fridman R, Gomez-Garcia R, Granados-Montiel J, Berebichez-Fastlicht E, Olivos-Meza A, Granados J et al (2017) The holy grail of orthopedic surgery: mesenchymal stem cells-their current uses and potential applications. *Stem Cells Int* 2017:2638305
- Brochhausen C, Lehmann M, Halstenberg S, Meurer A, Klaus G, Kirkpatrick CJ (2009) Signalling molecules and growth factors for tissue engineering of cartilage-what can we learn from the growth plate? *J Tissue Eng Regen Med* 3:416–429
- Cameron TL, Belluoccio D, Farlie PG, Brachvogel B, Bateman JF (2009) Global comparative transcriptome analysis of cartilage formation in vivo. *BMC Dev Biol* 9:20
- Cheng X, Yang T, Meng W, Liu H, Zhang T, Shi R (2012) Overexpression of GDF5 through an adenovirus vector stimulates osteogenesis of human mesenchymal stem cells in vitro and in vivo. *Cells Tissues Organs* 196:56–67
- Chubinskaya S, Segalite D, Pivkovsky D, Hakimiyan AA, Rueger DC (2008) Effects induced by BMPs in cultures of human articular chondrocytes: comparative studies. *Growth Factors* 26:275–283
- Coleman CM, Tuan RS (2003) Functional role of growth/differentiation factor 5 in chondrogenesis of limb mesenchymal cells. *Mech Dev* 120:823–836
- Coleman CM, Vaughan EE, Browe DC, Mooney E, Howard L, Barry F (2013) Growth differentiation factor-5 enhances in vitro mesenchymal stromal cell chondrogenesis and hypertrophy. *Stem Cells Dev* 22:1968–1976
- De Bari C, Dell'Accio F, Luyten FP (2004) Failure of in vitro-differentiated mesenchymal stem cells from the synovial membrane to form ectopic stable cartilage in vivo. *Arthritis Rheum* 50:142–150
- Dickhut A, Pelttari K, Janicki P, Wagner W, Eckstein V, Egermann M et al (2009) Calcification or dedifferentiation: requirement to lock mesenchymal stem cells in a desired differentiation stage. *J Cell Physiol* 219:219–226
- Enochson L, Stenberg J, Brittberg M, Lindahl A (2014) GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. *Osteoarthritis Cartilage* 22:566–577
- Evangeliou E, Chapman K, Meulenbelt I, Karassa FB, Loughlin J, Carr A et al (2009) Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. *Arthritis Rheum* 60:1710–1721
- Feng G, Wan Y, Balian G, Laurencin CT, Li X (2008) Adenovirus-mediated expression of growth and differentiation factor-5 promotes chondrogenesis of adipose stem cells. *Growth Factors* 26:132–142
- Hellingman CA, Davidson EN, Koevoet W, Vitters EL, van den Berg WB, van Osch GJ et al (2011) Smad signaling determines chondrogenic differentiation of bone-marrow-derived mesenchymal stem cells: inhibition of Smad1/5/8P prevents terminal differentiation and calcification. *Tissue Eng Part A* 17:1157–1167
- Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC et al (2005) Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. *Cytotherapy* 7:393–395
- Iamthanaporn K, Chareancholvanich K, Pornrattanameewong C (2015) Revision primary total hip replacement: causes and risk factors. *J Med Assoc Thai* 98:93–99
- Kania K, Colella F, Riemen AHK, Wang H, Howard KA, Aigner T et al (2020) Regulation of Gdf5 expression in joint remodelling, repair and osteoarthritis. *Sci Rep* 10:157
- Klammert U, Mueller TD, Hellmann TV, Wuerzler KK, Kotsch A, Schliermann A et al (2015) GDF-5 can act as a context-dependent BMP-2 antagonist. *BMC Biol* 13:77
- Klug A, Gramlich Y, Rudert M, Drees P, Hoffmann R, Weißberger M, et al. (2020) The projected volume of primary and revision total knee arthroplasty will place an immense burden on future health care systems over the next 30 years. *Knee Surg Sports Traumatol Arthrosc.* <https://doi.org/10.1007/s00167-020-06154-71-12>
- Kotsch A, Nickel J, Sebald W, Mueller TD (2009) Purification, crystallization and preliminary data analysis of ligand-receptor complexes of growth and differentiation factor 5 (GDF5) and BMP receptor 1B (BR1B). *Acta Crystallogr Sect F Struct Biol Cryst Commun* 65:779–783
- Lee DH, Lee SH, Song EK, Seon JK, Lim HA, Yang HY (2017) Causes and clinical outcomes of revision total knee arthroplasty. *Knee Surg Relat Res* 29:104–109
- Li J, Dong S (2016) The signaling pathways involved in chondrocyte differentiation and hypertrophic differentiation. *Stem Cells Int* 2016:2470351
- Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF (1998) Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. *Tissue Eng* 4:415–428
- Mackie EJ, Tatarczuch L, Mirams M (2011) The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. *J Endocrinol* 211:109–121
- Mancuso P, Raman S, Glynn A, Barry F, Murphy JM (2019) Mesenchymal stem cell therapy for osteoarthritis: the critical role of the cell secretome. *Front Bioeng Biotechnol* 7:9
- Mang T, Kleinschmidt-Dörr K, Ploeger F, Lindemann S, Gigout A (2020) The GDF-5 mutant M1673 exerts robust anabolic and anti-catabolic effects in chondrocytes. *J Cell Mol Med* 24:7141–7150
- Miyamoto Y, Mabuchi A, Shi D, Kubo T, Takatori Y, Saito S et al (2007) A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. *Nat Genet* 39:529–533

29. Miyazono K (1999) Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. *Bone* 25:91–93
30. Mobasheri A, Csaki C, Clutterbuck AL, Rahmanzadeh M, Shakibaei M (2009) Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. *Histol Histopathol* 24:347–366
31. Nickel J, Kotszsch A, Sebald W, Mueller TD (2011) Purification, crystallization and preliminary data analysis of the ligand-receptor complex of the growth and differentiation factor 5 variant R57A (GDF5R57A) and BMP receptor IA (BRIA). *Acta Crystallogr Sect F Struct Biol Cryst Commun* 67:551–555
32. Nickel J, Kotszsch A, Sebald W, Mueller TD (2005) A single residue of GDF-5 defines binding specificity to BMP receptor IB. *J Mol Biol* 349:933–947
33. Noth U, Tuli R, Osyczka AM, Danielson KG, Tuan RS (2002) In vitro engineered cartilage constructs produced by press-coating biodegradable polymer with human mesenchymal stem cells. *Tissue Eng* 8:131–144
34. Oldershaw RA, Baxter MA, Lowe ET, Bates N, Grady LM, Soncin F et al (2010) Directed differentiation of human embryonic stem cells toward chondrocytes. *Nat Biotechnol* 28:1187–1194
35. Parrish WR, Byers BA, Su D, Geesin J, Herzberg U, Wadsworth S et al (2017) Intra-articular therapy with recombinant human GDF5 arrests disease progression and stimulates cartilage repair in the rat medial meniscus transection (MMT) model of osteoarthritis. *Osteoarthritis Cartilage* 25:554–560
36. Reichert JC, Schmalzl J, Prager P, Gilbert F, Quent VM, Steinert AF et al (2013) Synergistic effect of Indian hedgehog and bone morphogenetic protein-2 gene transfer to increase the osteogenic potential of human mesenchymal stem cells. *Stem Cell Res Ther* 4:105
37. Reynard LN, Bui C, Syddall CM, Loughlin J (2014) CpG methylation regulates allelic expression of GDF5 by modulating binding of SP1 and SP3 repressor proteins to the osteoarthritis susceptibility SNP rs143383. *Hum Genet* 133:1059–1073
38. Scarfi S (2016) Use of bone morphogenetic proteins in mesenchymal stem cell stimulation of cartilage and bone repair. *World J Stem Cells* 8:1–12
39. Schreuder H, Liesum A, Pohl J, Kruse M, Koyama M (2005) Crystal structure of recombinant human growth and differentiation factor 5: evidence for interaction of the type I and type II receptor-binding sites. *Biochem Biophys Res Commun* 329:1076–1086
40. Seemann P, Schwappacher R, Kjaer KW, Krakow D, Lehmann K, Dawson K et al (2005) Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. *J Clin Invest* 115:2373–2381
41. Sieker JT, Kunz M, Weissenberger M, Gilbert F, Frey S, Rudert M et al (2015) Direct bone morphogenetic protein 2 and Indian hedgehog gene transfer for articular cartilage repair using bone marrow coagulates. *Osteoarthritis Cartilage* 23:433–442
42. Steinert AF, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Noth U (2007) Major biological obstacles for persistent cell-based regeneration of articular cartilage. *Arthritis Res Ther* 9:213
43. Steinert AF, Palmer GD, Pilapil C, Noth U, Evans CH, Ghivizzani SC (2009) Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. *Tissue Eng Part A* 15:1127–1139
44. Steinert AF, Proffen B, Kunz M, Hendrich C, Ghivizzani SC, Noth U et al (2009) Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. *Arthritis Res Ther* 11:R148
45. Steinert AF, Weissenberger M, Kunz M, Gilbert F, Ghivizzani SC, Gobel S et al (2012) Indian hedgehog gene transfer is a chondrogenic inducer of human mesenchymal stem cells. *Arthritis Res Ther* 14:R168
46. Sun K, Guo J, Yao X, Guo Z, Guo F (2021) Growth differentiation factor 5 in cartilage and osteoarthritis: a possible therapeutic candidate. *Cell Prolif* 54:e12998
47. Tian HT, Zhang B, Tian Q, Liu Y, Yang SH, Shao ZW (2013) Construction of self-assembled cartilage tissue from bone marrow mesenchymal stem cells induced by hypoxia combined with GDF-5. *J Huazhong Univ Sci Technol Med Sci* 33:700–706
48. Venkatesan JK, Ekici M, Madry H, Schmitt G, Kohn D, Cucchiari M (2012) SOX9 gene transfer via safe, stable, replication-defective recombinant adeno-associated virus vectors as a novel, powerful tool to enhance the chondrogenic potential of human mesenchymal stem cells. *Stem Cell Res Ther* 3:22
49. Wagenbrenner M, Heinz T, Horas K, Jakuscheit A, Arnholdt J, Herrmann M et al (2020) The human arthritic hip joint is a source of mesenchymal stromal cells (MSCs) with extensive multipotent differentiation potential. *BMC Musculoskelet Disord* 21:297
50. Weber M, Renkawitz T, Voellner F, Craiovan B, Greimel F, Worlicek M et al (2018) Revision Surgery in Total Joint Replacement Is Cost-Intensive. *Biomed Res Int* 2018:8987104
51. Weissenberger M, Weissenberger MH, Gilbert F, Groll J, Evans CH, Steinert AF (2020) Reduced hypertrophy in vitro after chondrogenic differentiation of adult human mesenchymal stem cells following adenoviral SOX9 gene delivery. *BMC Musculoskelet Disord* 21:109
52. Weißberger M, Weißberger MH, Wagenbrenner M, Heinz T, Reboredo J, Holzapfel BM et al (2020) Different types of cartilage neotissue fabricated from collagen hydrogels and mesenchymal stromal cells via SOX9, TGFB1 or BMP2 gene transfer. *PLoS ONE* 15:e0237479

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)